Division of Hematology and Oncology

October 29, 2020

Rini to lead NCI study of COVID-19 in cancer patients

Brian Rini, MD, is leading a study launched by the National Cancer Institute (NCI) that will closely monitor cancer patients who acquire COVID-19 with the goal of providing highly detailed data to guide future care.

By Tom Wilemon
October 21, 2020

Park named director of Hematology and Oncology at VICC

After serving as interim director since Jan. 1, Ben Ho Park, MD, PhD, Donna S. Hall Professor of Breast Cancer Research at Vanderbilt University Medical Center, has been named director of the Division of Hematology and Oncology.

By Tom Wilemon
September 24, 2020

VICC leading first global study of MDS/MPN overlap syndrome

Overlap syndromes are distinct blood cancers that present with features of both myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN).

By Tom Wilemon
July 30, 2020

Iams honored by National Comprehensive Cancer Network

Wade Iams, MD, MSCI, assistant professor of Medicine, is the recipient of a National Comprehensive Cancer Network Foundation Young Investigator Award.

By Tom Wilemon
June 24, 2020

Study shows better option for treatment of inoperable anal cancer

People with inoperable anal cancer treated with carboplatin-paclitaxel had fewer complications and lived longer than those who received another chemotherapy that has been more often administered.

By Tom Wilemon
May 28, 2020

Multinational consortium reports COVID-19 impact on cancer patients

People with cancer sickened by COVID-19 have a crude death rate of 13%, according to the largest series of data released thus far from a multinational perspective. The data on more than 900 patients, published May 28 in The Lancet and simultaneously presented at ASCO20 Virtual, also revealed cancer-specific factors associated with increased mortality.

By Tom Wilemon
April 30, 2020

Initiative to explore COVID-19 outcomes in cancer patients

A multi-institutional consortium led by Vanderbilt-Ingram Cancer Center (VICC) is collecting data on cancer patients with COVID-19 as part of a rapid effort to understand the unique effects the coronavirus has on this vulnerable population.
By Tom Wilemon
April 23, 2020

Health workers sought for hydroxychloroquine study

Health care workers at Vanderbilt University Medical Center at high risk of exposure to COVID-19 can participate in a randomized, controlled clinical trial testing the effectiveness of the drug hydroxychloroquine (HCQ) in preventing infection.
By Bill Snyder
March 5, 2020

One-two punch for cancer

A drug combination effectively killed aggressive blood cancers in cell and animal models; now it’s being tested in patients.
By Sanjay Mishra
February 20, 2020

Post-transplant diabetes may be reversible: study

Post-transplantation diabetes mellitus (PTDM), a common complication of immunosuppressive drugs that are given to prevent transplant rejection, may be reversible and at least partially preventable, researchers at VUMC report.
By Bill Snyder
February 5, 2020

Vanderbilt-Ingram Cancer Center researchers included in ASCO annual report

Two researchers from Vanderbilt-Ingram Cancer Center (VICC) are featured in Clinical Cancer Advances 2020: ASCO’s Annual Report on Progress Against Cancer.
By Tom Wilemon
February 5, 2020

Vanderbilt-Ingram Cancer Center patient first for new cell engineering platform

Rhea Dodd is the first patient treated with an experimental cancer vaccine derived from a completely new cell engineering platform.
By Tom Wilemon
January 9, 2020

Park named interim Hematology and Oncology director

Ben Ho Park, MD, PhD, has been named interim director of the Division of Hematology and Oncology.
By Tom Wilemon
1 … 5 6 7 8 9 … 13